Tharimmune

Tharimmune plans to initiate a Phase 2 study of TH104 for moderate-to-severe pruritus in PBC patients in 2025, following positive Phase 1 results and regulatory feedback. The company achieved milestones in manufacturing, clinical trials, and regulatory progress in 2024, and expanded its Board of Directors with the appointment of Sanam Parikh.

Tharimmune, Inc. announced a $2.02 million private placement, issuing 961,446 shares and warrants for 480,723 additional shares, priced at $2.10 and $2.031 respectively. Proceeds will fund clinical development, including TH104 for chronic pruritus in PBC, and general working capital. The transaction is expected to close on December 9, 2024.

Tharimmune, Inc. announces CEO Randy Milby's participation in the 2024 Spartan Capital Investor Conference on Nov 4 in NYC and CMA Nir Barak's poster presentation on TH104 at AASLD's The Liver Meeting® 2024 on Nov 18 in San Diego.

Tharimmune, Inc. received positive feedback from the EMA on TH104, its lead candidate for pruritus in PBC, with guidance on Phase 2 and 3 trials. The EMA endorsed the strategy and found the Phase 2 study design acceptable, providing general guidance for Phase 3. Tharimmune plans to initiate a Phase 2 trial in the coming months, expecting topline data in 2025.

Tharimmune to acquire Intract, forming a transformative oral biologics company. Intract shareholders will own 49% of the combined entity, expected to close in 1Q25. The merger aims to drive pipeline growth and strengthen Tharimmune's position in the biologics market.